The invention relates to the use of the fraction of STIM1 localized to the plasma membrane as a therapeutic target in CLL and SLE by modulating its presence or its activity.
Chronic lymphocytic leukemia (CLL) is the leading cause of leukemia in Western countries. To date, no treatment including the novel therapies targeting the B cell receptor (BCR) pathway (e.g. anti-CD20 monoclonal antibodies (mAb), BCR kinase inhibitors) offers a complete remission. It is noteworthy that the rate of treatment interruptions and toxicity remain elevated for these patients.
Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by the presence of autoreactive lymphocytes and of antinuclear auto-antibodies (ANA). It is a multisystemic disease, with heterogenous clinical manifestations. SLE may affect all organs.
Presence of the marker solely on affected cells
Expression by the immune cells of the STIM1 protein at the plasma membrane facilitates the accessibility of this target
Stade de développement
IN VIVO - Preuve de concept
Laboratoire de recherche
UMR 1227 - LBAI
Équipe de recherche
LYMPHOCYTES B ET AUTOIMMUNITÉ
Propriété intellectuelle associée
EP : EP14290232 - filed on the 08-06-2014
WO - AT,BE,BE,CA,CH,CH,CN,CN,DE,DE,DK,EP,ES,FI,FR,FR,GB,GB,